Abstract: The present invention features the present invention features a tablet including at least one pharmaceutically active ingredient, wherein the shape of said tablet includes at least one major face wherein: (i) the peak penetration resistance at the perimeter of said major face of the tablet is at least about 10% greater than the peak penetration resistance at the center of said major face; and (ii) the tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds, and a machine and method for manufacture of such tablet.
Type:
Grant
Filed:
March 21, 2011
Date of Patent:
October 14, 2014
Assignee:
McNeil-PPC, Inc.
Inventors:
Christopher E. Szymczak, Frank J. Bunick, Harry S. Sowden, Joseph R. Luber, Leo B. Kriksunov
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
Abstract: Formulations of fenoldopam are disclosed for repeated administration or continued slow release administration, over prolonged periods of time or targeted slow and regulated delivery. The formulations include those formulations that increase the bioavailability of fenoldopam after oral intake, particularly lipid based nano dispersions and pronanodispersions and surfactant rich formulations. This may be accomplished by entrapment in nanoparticles or liposomal formulations or conjugation to a polymer or small molecule via a soft bond.
Abstract: Tablets for the controlled release of an active ingredient in a zero-order or near zero-order fashion are provided. The tablet includes a core and a coating. The core includes at least one active pharmaceutical agent and a polyethylene oxide with a molecular weight of between about 1,000,000 and 10,000,000, preferably between about 4,000,000 and 8,000,000. The core material is optionally, but preferably, coated with a cellulosic material. The active pharmaceutical agent can be hydrophilic, hydrophobic, or amphiphilic. When the active pharmaceutical agent is a hydrophilic agent, it is preferred that the coating is a relatively hydrophobic cellulose, such as ethylcellulose or propylcellulose. However, if the tablet is uncoated, it can provide a near-zero-order release rate rather than a zero-order release rate.
Abstract: The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments.
Type:
Application
Filed:
April 10, 2014
Publication date:
October 9, 2014
Applicant:
ICEUTICA PTY LTD.
Inventors:
Aaron DODD, Felix MEISER, Marck NORRET, Adrian RUSSELL, H. William BOSCH
Abstract: The present invention relates to an orodispersible tablet comprised of, by weight: a maximum of 15% of a low-dose, therapeutically active substance; from 55% to 70% of mannitol of a particle size between 30 ?m and 300 ?m; at least 2% of maltodextrin; from 3.5% to 8% of croscarmellose sodium; from 10% to 20% of microcrystalline cellulose; from 0.5% to 1.5% of magnesium stearate; and from 1% to 5% of flavoring (s) and sweetener (s).
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Abstract: The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I wherein the definitions are described in claim 1, or pharmaceutically acceptable acid addition salts thereof and a water soluble poloxamer in which the compound of formula I and the water soluble poloxamer are processed by hot melt extrusion, and then the hot melt extrudate is mixed with other ingredients to form a tablet, that is optionally coated with a composition comprising an immediate release film coating system and purified water. The invention also relates to such pharmaceutical compositions and hot melt extrudates.
Type:
Grant
Filed:
March 7, 2013
Date of Patent:
October 7, 2014
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Hashim A. Ahmed, Susanne Page, Navnit Hargovindas Shah
Abstract: Pharmaceutical formulations suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a base salt of a compound of Formula (I) and a release rate controlling composition comprising a solubilizing agent, a gelling agent, and a water soluble filler; wherein R1, R2, R3 and R4 are defined herein. The formulations are suitable for use in the inhibition of HIV integrase, the treatment and prophylaxis of HIV infection, and the treatment, prophylaxis and delay in the onset of AIDS.
Type:
Grant
Filed:
December 2, 2005
Date of Patent:
October 7, 2014
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Nazaneen Pourkavoos, James R. Ney, Maria T. Cruanes, Yunhui Wu, Saurabh A. Palkar
Abstract: A dissolvable medication administration bag for the safe and effective crushing and administration of medication to patients who have difficulty swallowing pills is disclosed herein. In some embodiments, the dissolvable medication administration bag is constructed in accordance with a pill crusher pouch embodiment into which a pill is placed prior to being crushed and subsequently the whole of pouch and the crushed pill contents are dissolved into a liquid, e.g. a beverage, as a means of reducing health hazards associated with current pill crushing practices such as inadvertent direct contact and aerosolization with subsequent inhalation of the crushed medication. In other embodiments, the dissolvable medication administration bag is constructed in accordance with a pre-packaged medicine dosage administration bag embodiment wherein the whole of the pre-packaged bag and its powdered or liquid form medication contents are dissolved into a liquid with no need for crushing.
Abstract: The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.
Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
Abstract: A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m2/g, and c) 0-40% by weight of further excipients, with the proviso that the total amount of components a) to c) corresponds to 100% by weight, where at least 50% of the surface of the ibuprofen crystals are covered with the finely divided excipient.
Type:
Grant
Filed:
October 5, 2006
Date of Patent:
September 30, 2014
Assignee:
BASF SE
Inventors:
Kathrin Meyer-Boehm, Karl Kolter, Anisul Quadir
Abstract: A process for local permucosal diffusion of amino acid salts of low dosage lipophlic non-steroidal anti-inflammatory or anti-mycotic molecules for an aqueous medicine for the treatment of bucco-pharyngeal ailments is disclosed. Compositions and tablets implementing this diffusion process are also disclosed.
Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.
Type:
Application
Filed:
June 5, 2014
Publication date:
September 25, 2014
Applicant:
Novartis AG
Inventors:
Yatindra Joshi, James Kowalski, Jay Parthiban Lakshman, Alan Edward Royce, Wei-Qin Tong, Madhav Vasanthavada
Abstract: The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubric ants, colorants and combinations thereof.
Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
Type:
Grant
Filed:
December 10, 2010
Date of Patent:
September 23, 2014
Assignee:
Collegium Pharmaceutical, Inc.
Inventors:
Roman V. Rariy, Alison B. Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi
Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
Type:
Grant
Filed:
December 23, 2008
Date of Patent:
September 23, 2014
Assignee:
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Abstract: A method to treat a condition in a patient comprising administering to the patient a therapeutically effective amount of a NH4Cl dosage form, a method for stimulating endogenous interferon production, and related methods, systems and dosage form housings.
Abstract: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.
Abstract: There is disclosed a formulation for creating a rapid penile erection within 30 minutes. In an embodiment, a lozenge has a preparation configured to create a rapid penile erection. The preparation is effective to create the rapid penile erection with sildenafil citrate in a range of 50-100 mg. The preparation is effective to create the rapid penile erection with tadalafil in a range of 5-40 mg. The preparation is effective to create the rapid penile erection with vardenafil hydrochloride in a range of 5-40 mg. In various embodiments, the formulation includes a solvent configured to permeate skin. Other embodiments are also disclosed.
Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
Type:
Grant
Filed:
June 8, 2011
Date of Patent:
September 16, 2014
Assignee:
Forest Laboratories Holdings Limited
Inventors:
Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier
Abstract: One possible embodiment of the invention may be an oral dosage apparatus comprising of a sealed, digestible container having an exterior that defines and seals a respective interior; the interior containing one or more non-homeopathic remedies; and the exterior presenting one or more homeopathic products. Another version of the invention may be a method of manufacturing an oral dosage apparatus comprising of the following steps of providing one or more non-homeopathic remedies and one or more non-homeopathic remedies; providing a sealed, digestible container having an exterior that correspondingly defines and seals a respective interior containing one or one or more non-homeopathic remedies; affixing one or more homeopathic remedies to the exterior.
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
Type:
Application
Filed:
May 23, 2014
Publication date:
September 11, 2014
Applicant:
Vertex Pharmaceuticals Incorporated
Inventors:
Eleni Dokou, Shahla Jamzad, John P. Caesar, JR., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
Abstract: A solid pharmaceutical dosage form [19] has micro- or nanostructures [10a, 10b, 10c, 10d] impressed on the surface thereof or an interface thereof. The dosage form [19] includes a suitable quantity and distribution of ingredients, such as one or more dyes, so as to enhance the optical contrast effect, C, caused by the micro- or nanostructures so that the micro- or nanostructures are observable by the human eye and thereby able to provide anti-counterfeiting characteristics to the dosage form.
Type:
Application
Filed:
April 16, 2010
Publication date:
September 11, 2014
Applicant:
I-Property Holding Corp.
Inventors:
Stefan Klocke, Harald Walter, Alexander Stuck
Abstract: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.
Abstract: This invention relates to a bilayer pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and atorvastatin, or a pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Type:
Application
Filed:
October 20, 2012
Publication date:
September 4, 2014
Inventors:
Sutthilug Sotthivirat, Edward J. Fagan, Katherine H. Chin, Abraham B. Woldu, Charles DeLuca, Decheng Ma, Walter R. Wasylaschuk, Bhagwant Rege
Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
Abstract: A tablet showing regulated variation in dissolution from lot to lot which contains from about 3 to about 50% by weight (w/w), based on the whole tablet, of (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, magnesium stearate and hydroxypropylcellulose having a viscosity of about 1 to about 4 mPa·s.
Abstract: The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.
Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
Type:
Grant
Filed:
July 29, 2013
Date of Patent:
August 26, 2014
Assignee:
Purdue Pharma L.P.
Inventors:
Christopher Breder, Curtis Wright, Benjamin Oshlack
Abstract: In the process of coating pharmaceutical tablets in a moving bed, the temperature of the tablets is measured by incorporating a temperature transducer in the form of tablet into the bed of tablets, and transmitting temperature data to an external receiver by wireless telemetry.
Abstract: The present invention provides a pharmaceutical composition comprising the following active ingredients: 1) an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, 2) pioglitazone or a pharmaceutically acceptable salt thereof; and 3) rosuvastatin or a pharmaceutically acceptable salt thereof. The present invention also provides use of the pharmaceutical composition in preparing a medicament for treating hypertension or metabolic syndrome. The pharmaceutical composition of the present invention can treat hypertension or metabolic syndrome, while effectively controlling the incidence of associated cardiovascular diseases and more potently improving survival prognosis in hypertensive patients. When blood pressure is lowered to desired level, the risk factors such as cardiovascular diseases are rectified, metabolic disorders and prognosis of patients are improved, and survival rate of hypertensive patients is raised.
Abstract: The invention relates to a process for the preparation of a pharmaceutical intermediate, comprising the steps of (i) mixing (a-i) sildenafil base, (b-i) wicking agent, (c-i) disintegrant, (d-i) optionally glidant; (ii) compacting the mixture; and (iii) milling the compacted material; and to an intermediate obtainable by that process. In addition, the invention relates to a process for the preparation of an orally dispersible tablet (hereinafter also referred to as an “orodispersible tablet”) comprising the intermediate of the invention, and to orodispersible tablets obtainable by that process.
Type:
Grant
Filed:
December 22, 2010
Date of Patent:
August 19, 2014
Assignee:
ratiopharm GmbH
Inventors:
Sven Winter, Max-Werner Scheiwe, Dieter Swatschek
Abstract: The present invention relates to a novel process for the preparation of a granulate comprising a calcium-containing compound as an active substance. The method comprises a method for the preparation of a granulate comprising a calcium-containing compound as an active substance, the method comprising, i) feeding a granulation chamber with a composition comprising the calcium-containing compound, ii) wet-massing the composition with a granulation liquid optionally comprising a pharmaceutically acceptable binder for a time period of at the most 30 sec to obtain a wet granulate, iii) drying the thus obtained wet granulate. A granulate obtained by the present method is especially suitable in the preparation of solid dosage forms, in particular in the preparation of tablets.
Type:
Grant
Filed:
February 2, 2006
Date of Patent:
August 19, 2014
Assignee:
Takeda Nycomed AS
Inventors:
Poul Egon Bertelsen, Peder Mohr Olsen, Carsten Martini Nielsen, Magnus Wilhelm Tolleshaug
Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
Type:
Grant
Filed:
July 14, 2011
Date of Patent:
August 19, 2014
Assignee:
Genzyme Corporation
Inventors:
Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner
Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.
Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Type:
Grant
Filed:
September 25, 2013
Date of Patent:
August 19, 2014
Assignee:
ZS Pharma, Inc.
Inventors:
Donald Jeffrey Keyser, Alvaro F. Guillem
Abstract: Taste masked multi-layered particles include an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and including a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture including 60-90% (w/w) EC and 10-40% (w/w) HPMC, where the pharmaceutically active ingredient is water-soluble and includes either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions including such particles.
Type:
Application
Filed:
April 16, 2014
Publication date:
August 14, 2014
Applicant:
BOEHRINGER INGELHEIM VETMEDICA GMBH
Inventors:
Martin FOLGER, Stefan LEHNER, Annette GRAVE, Norbet POELLINGER, Randolph SEIDLER
Abstract: The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation.
Abstract: The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4?-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.
Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
August 12, 2014
Assignee:
ZS Pharma, Inc.
Inventors:
Donald Jeffrey Keyser, Alvaro F. Guillem
Abstract: A delivery vehicle including a mixture of: a) an effective amount of an expander activatable by a wetting agent and, b) a treatment agent. The expander and treatment agent intermingled and compressed so as to form a substantially solid delivery vehicle. The solid delivery vehicle, on exposure to a volume of wetting agent forms a predetermined volume of a paste containing the treatment agent; and the volume of paste is adapted for delivery of the treatment agent.
Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
Type:
Grant
Filed:
July 11, 2012
Date of Patent:
August 5, 2014
Assignee:
Elcelyx Therapeutics, Inc
Inventors:
Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.
Type:
Grant
Filed:
September 11, 2006
Date of Patent:
August 5, 2014
Assignee:
Angelini Pharma Inc.
Inventors:
Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
Abstract: The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic.
Abstract: The present invention is a composition for coating comprising a wet-milled product obtained by suspending low-substituted cellulose ether having a molar substitution of from 0.05 to 1.0 per anhydrous glucose unit in water and then applying a shear force to the aqueous dispersion. The present invention is also a coated preparation prepared using the composition for coating so as to mask an unpleasant taste and to control a sticky or slimy feel by administration.
Abstract: The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), or a hydrochloride, or a pharmaceutically acceptable addition salt thereof. In particular, the disclosure relates to the synthesis, purification and characterization of an Isometheptene isomer mucate crystal 2, wherein the Isometheptene isomer 2 is stereochemically characterized as (R)-enantiomer, respectively. The Isometheptene (R)-enantiomer activity indicates a selective centrally acting selective ligand for Imidazoline subtype 1 (I1) receptor sites; and more specifically, the disclosure provides an antihypertensive composition for treatment of migraine and other neurovascular or neurogenic pain from abdominal distress. (R)-Isometheptene enantiomer or isomer 2 may be an anti-hypertensive agent with lower side effects than the racemate form. Therefore (R)-Isometheptene is believed to be effective against episodic tension-type headaches (ETTH).
Type:
Application
Filed:
January 17, 2014
Publication date:
July 31, 2014
Applicant:
TONIX PHARMACEUTICALS INC.
Inventors:
SETH LEDERMAN, BRUCE DAUGHERTY, LELAND J. GERSHELL, DARRYL RIDEOUT, ANDREW KAWASAKI